Aethlon Medical Inc (AEMD) Stock Analysis
Verdict: AVOID
Extreme cash burn ($7M/yr) against an 8-month cash runway ($5M) makes AEMD a severe dilution trap despite speculative after-market pops.
Investment score: 16/100
Analysis as of
Is Aethlon Medical Inc stock worth reviewing? AI model thesis
The AI model rates Aethlon Medical as an AVOID due to zero revenue, rapid cash depletion, and high dilution probability.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 15/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Aethlon Medical Inc opportunities and risks
What speaks for AEMD
- Clinical trial progress for Hemopurifier in oncology or infectious diseases
What speaks against AEMD
- Imminent equity dilution due to 8-month cash runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AEMD | n/a | 0.0x | 0.5x | 0.0% | 0.0% | -131931.8% |
| LGMK | n/a | 0.1x | 0.5x | 56.9% | -50.2% | -437.5% |
| IVF | n/a | 0.2x | n/a | 33.3% | -70.2% | -262.7% |
| PFSA | n/a | 0.0x | n/a | 0.0% | 0.0% | -558.7% |
| LLBO | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| UAHC | 170.0x | 0.0x | n/a | 0.0% | 0.0% | 72.2% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -262.7% |
Frequently asked questions about Aethlon Medical Inc (AEMD)
Is AEMD stock a good investment?
The cached TradeMates AI model rates Aethlon Medical Inc as AVOID with an investment score of 16/100. The AI model rates Aethlon Medical as an AVOID due to zero revenue, rapid cash depletion, and high dilution probability. This is algorithmic model output, not personal investment advice.
Is AEMD stock a buy?
The TradeMates model verdict for AEMD is AVOID with an investment score of 16/100. Treat this as a model signal to review, not a personal buy recommendation.